AccuGenomics develops “STANDARDIZED” molecular gene expression tests that provide genomic data to diagnose and monitor cancer treatment for the patient.  In AccuGenomics' proprietary molecular diagnostics tests the proprietary mixtures of internal standards provide quantitative, standardized, numerical measurements that enable gene expression based molecular diagnostics tests to be standardized and used for therapeutic intervention, monitoring and diagnosis of disease.   

AccuGenomics plans to commercialize and launch its exciting pipeline of standardized genomic tests in today’s high-growth diagnostics market. AccuGenomics continues to work with the FDA utilizing its strong intellectual property - Mixture of Internal Standards - along with its expertise in standardization and quality control of molecular diagnostic test results to gain regulatory approval.

Currently, AccuGenomics is pursuing FDA approval for its Standardized BCR-ABL reagents. Patients currently are being recruited for a clinical trial of the lung cancer risk test.

beats by dre cheap legend blue 11s jordan 11 legend blue sac louis vuitton black infrared 6s jordan 14 black toe michael kors outlet black infrared 6s lebron 11 jordan retro 6 cheap jordans black infrared 6s legend blue 11s coach outlet online jordan 11 legend blue legend blue 11s louis vuitton outlet jordan retro 11 beats by dre outlet jordan 6 black infrared black infrared 6s kate spade outlet jordan 6 black infrared louis vuitton outlet jordan 11 legend blue coach factory outlet Legend Blue 11s lebron 12 jordan 6 black infrared louis vuitton outlet michael kors outlet online beats by dre cheap coach black friday north face black friday black infrared 6s beats by dre black friday legend blue 11s legend blue 11s beats by dre black friday jordan retro 11